Prof Mejean speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about treating metastatic renal cell carcinoma (mRCC) with sunitinib alone or sunitinib and surgery.
He outlines the stratification for patients recruited to the trail, in which the benefit of sunitinib with or without surgery for medium-risk patients was unknown, and the observed impact on disease survival.
For more on these results, watch Dr Mejean present the data in a press conference here, and read our news coverage here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.